GenSight Biologics Reports Full-Year 2025 Financial Results in Line with Expectations

GenSight Biologics Confirms Full-Year 2025 Financial Results in Line with Prior Estimates GenSight Biologics a clinical-stage biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has confirmed that its final consolidated financial results…










